2019
Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011.
Dinan MA, Wilson LE, Reed SD. Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011. Journal Of The National Comprehensive Cancer Network 2019, 17: 245-254. PMID: 30865923, DOI: 10.6004/jnccn.2018.7097.Peer-Reviewed Original ResearchConceptsLow-risk diseaseHigh-risk patientsHigh-risk diseaseRS testingMedicare beneficiariesPrimary analysisEstrogen receptor-positive breast cancerReceptor-positive breast cancerLower chemotherapy useIntermediate-risk diseaseIntermediate-risk patientsRetrospective cohort studyGenomic testingSEER-Medicare dataChemotherapy useCohort studyMultivariable analysisBreast cancerChemotherapy costsLow overall useMAIN OUTCOMEMedicare populationPatientsHigher overall costsDisease
2013
Oral Contraceptive Pills as Primary Prevention for Ovarian Cancer
Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral Contraceptive Pills as Primary Prevention for Ovarian Cancer. Obstetrics And Gynecology 2013, 122: 139-147. PMID: 23743450, DOI: 10.1097/aog.0b013e318291c235.Peer-Reviewed Original ResearchConceptsOral contraceptive pillsUse of OCPOvarian cancer incidenceOCP useContraceptive pillsCancer incidenceOvarian cancerDuration-dependent reductionDuration-response relationshipOvarian cancer riskDuration of useCohort studyCochrane DatabasePrimary preventionSTUDY SELECTIONInclusion criteriaCancer riskDiscordant decisionsGeneral populationPrimary analysisSystematic reviewTeam reviewIncidenceSignificant reductionMore years